ORANGEBURG, N.Y., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, today announced that effective today, Howard Zauberman, currently serving as Interim Chief Executive Officer, has been promoted to Chief Executive Officer and President. The Board also elected Mr. Zauberman to the Board of Directors to serve as a Class I director.
"Howard's work on behalf of Vision-Sciences over the last few months has moved the company in the right direction," said Lewis Pell, the Chairman of the Board and co-founder. "In recognition of the progress he has made, we made the decision to appoint Howard as our permanent CEO, and we look forward to having him join our Board."
Mr. Zauberman added, "I have been working with Vision-Sciences since May and believe that we have made significant progress to date. I look forward to working with the Company, the full Board and the management team as we seek to execute our strategy of growth and expansion for our innovative EndoSheath technology."Mr. Zauberman, 60, has over 30 years of experience as a leader in the medical products industry. Prior to joining Vision-Sciences in May 2013, Mr. Zauberman was Vice President of Business Development at Henry Schein, Inc., a leading global healthcare distributor serving office based medical practitioners, from 2005 through 2012. Mr. Zauberman also served as a Special Venture Partner at Galen Partners, a healthcare growth equity and late stage venture capital firm, focused on technology enabled services, medical devices and specialty pharmaceuticals. Prior to this, Mr. Zauberman held senior management positions at ETHICON, Inc. a Johnson & Johnson company and Pfizer, Inc. Mr. Zauberman has a Masters of Engineering Management from Northwestern University, a Bachelor of Science from Columbia University in mechanical engineering and a Bachelors degree from Queens College.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts